MedTrace Logo

ALADDIN Study: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation

NCT00063310 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2009-12-11

No results posted yet for this study

Summary

ALADDIN is a research study to investigate the safety and effectiveness of leuprolide (a hormone drug) to improve the cognitive function and slow the progression of Alzheimer's disease (AD). In women leuprolide is commonly used to treat hormone related conditions such as endometriosis and uterine fibroids. The study will include treatment of women 65 years and older with mild to moderate Alzheimer's disease who reside in the community.

Conditions

  • Alzheimer Disease

Interventions

DRUG

Leuprolide acetate

Sponsors & Collaborators

  • Voyager Pharmaceutical Corporation

    lead INDUSTRY

Principal Investigators

  • Richard L. Bowen, MD · Voyager Pharmaceutical Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-03-31
Primary Completion
2006-02-28
Completion
2006-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00063310 on ClinicalTrials.gov